Recent News About AbbVie
By Business Daily | Mar 15, 2025
AbbVie has released the final data from its Phase 3 MIRASOL trial, demonstrating a notable survival benefit for ELAHERE (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
By Business Daily | Mar 4, 2025
AbbVie has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
By Business Daily | Mar 3, 2025
AbbVie and Gubra have announced a license agreement to develop an amylin analog, GUB014295, for obesity treatment.
By A. I. Benavidez | Feb 26, 2025
AbbVie is set to participate in the TD Cowen's 45th Annual Health Care Conference, scheduled for Wednesday, March 5, 2025.
By A. A. Sanchez | Feb 14, 2025
AbbVie has announced that its board of directors unanimously elected CEO Robert A. Michael to also serve as chairman, effective July 1, 2025.
By A. A. Sanchez | Feb 13, 2025
The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share.
By A. A. Sanchez | Feb 12, 2025
AbbVie and Xilio Therapeutics have entered into a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies.
By A. A. Sanchez | Feb 12, 2025
Allergan Aesthetics, a company under AbbVie, is set to open three new Allergan Medical Institute (AMI) Training Centers in the United States.
By K. R. Nelson | Feb 7, 2025
The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO, a combination of aztreonam and avibactam, for treating adults with complicated intra-abdominal infections (cIAI).
